Join our daily newsletter At The Bell to receive exclusive market insights
- NeuroScientific Biopharmaceuticals (NSB) confirms the safety of its lead drug candidate, EmtinB
- The company has seen positive outcomes from its preclinical safety and toxicology program to support commencement of first in-human clinical trials
- From this result, the company is soon expecting to receive approval from the Human Research Ethics Committee
- This will allow NSB to commence its first human clinical trial for EmtinB during the first half of 2022
- NSB shares are up 9.62 per cent and are trading at 28.5 cents per share
NeuroScientific Biopharmaceuticals (NSB) has confirmed the safety of its lead drug candidate, EmtinB.
EmtinB significantly reduced inflammatory growth proteins, or cytokines, which are closely tied to multiple diseases.
The company has seen positive outcomes from its preclinical safety and toxicology program to support commencement of first in-human clinical trials.
NSB reported that EmtinB showed an impressive safety profile in multiple animal species, including pivotal good laboratory practice (GLP) toxicology studies of daily doses up to 20 times above the predicted efficacious dose range in humans, with no major adverse effects or toxicology findings attributed to EmtinB.
From this result, the company is soon expecting to receive approval from the Human Research Ethics Committee which will allow NSB to commence its first human clinical trial for EmtinB during the first half of 2022.
“We are excited to report the outstanding safety outcomes for EmtinB and the successful completion of the preclinical safety and toxicology program to support initiation of phase one clinical studies for our neurology indications,” Managing Director and CEO Matt Liddelow said.
“This safety data provides clear validation that we have met all requirements of achieving the significant milestone of advancing our novel lead drug candidate EmtinB™ into the clinical development phase and we have been working closely with our clinical development partner Linear Clinical Research to execute on our first-in-human
clinical trial in 1H 2022.”
On the market, NSB was up 9.62 per cent and was trading at 28.5 cents per share at market close.
